美托洛尔治疗慢性心力衰竭的临床疗效观察

目的：观察酒石酸美托洛尔治疗慢性心力衰竭（CHF）的临床疗效及安全性。方法：将66例慢性心力衰竭患者随机分成两组，治疗组33例给予内科常规抗心力衰竭治疗，对照组33例在常规治疗的基础上加用酒石酸美托洛尔治疗。治疗前后观察静息心率（HR）、收缩压（SBP）、舒张压（DBP）、心功能级别、左室舒张末内径（LVEDD）、左室收缩末期内径（LVESD）左室射血分数（LVEF）。结果：两组患者的各项指标在治疗后均较治疗前有明显改善，但治疗组较对照组改善更为显著，其临床疗效优于对照组（P〈0．05）。结论：酒石酸美托洛尔可明显改善CHF患者心功能，提高生存率，是一种安全、有效的临床治疗方法。

Metoprolol patients with chronic heart failure the clinical curative effect of observation

Objective： To observe metoprolol tartrate treatment of chronic heart failure （CHF） of the clinical efficacy and safety. Methods： 66 patients with chronic heart failure patients were randomly divided into two groups ： treatment group in 33 cases were given medical conventional anti heart failure treatment group in 33 patients based on routine treatment combined with metoprolol tartrate treatment. We observed before and after treatment resting heart rate （HR）, systolic blood pressure （SBP）, diastolic pressure （DBP）, and cardiac function level, left ventricular end-diastolic diameter （LVEDD）, left ventricular end-systolic diameter （LVESD） left ventricular ejection fraction （LVEF） changes. Results： Two sets of patients each index after treatment were relatively before treatment were obviously improved, but the treatment group is more significant than the control group to improve, the clinical curative effect than in control group （P〈0.05）. Conclusions： Metoprolol tartrate can greatly improve cardiac function, improve survival in patients with CHF, is a safe and effective clinical treatment.